Novartis AG Stock News

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed ownersh

Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea

Novartis AG (NYSE:NVS ) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Global H

Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the

AbbVie should be poised to return to rapid growth and recently boosted its dividend. Novartis' spin-off of Sandoz doesn't diminish its attractiveness for income investors.

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug

Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a decent collection of high-growth products and pipeline

AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.

Investors are worried about soaring interest rates, a pending government shutdown, wars around the world, and a recession looming next year. History is very clear, market timing is the WORST thing you

Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates.

Despite multiple macroeconomic issues in the past year, the market looks to finally be turning back up as 2024 nears. In 2022 and 2023, unexpected downturns from the bear market, threats of an impend

Novartis AG (NYSE:NVS ) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.